The COVID-19 vaccine developed by Pfizer and BioNTech is effective at preventing symptomatic and severe disease in people with some chronic ...
www.channelnewsasia.com
The vaccine was 80 per cent effective against symptomatic infection for people with heart or chronic kidney diseases, 86 per cent for people with type 2 diabetes, 75 per cent for cerebrovascular disease, and 84 per cent for people suffering from immunodeficiency, according to the Clalit Research Institute study.
For people who were vaccinated and were already suffering three or more chronic conditions or risk factors, such as heart disease, neurological disease, chronic kidney disease, chronic lung disease, smoking, pregnancy or obesity, the research shows it was 88% effective in preventing symptomatic infection.
It was more than 90 per cent effective against severe disease for people with type 2 diabetes, heart or cerebrovascular disease and 100 per cent for people suffering from immunodeficiency.
The data is the latest from Israel where a universal and digitised healthcare system and the speedy vaccination programme have allowed researchers insights into the vaccine's potency. Clalit covers more than half of Israel's population.